Luke Evnin

Ex­clu­sive: A long­time VC takes on his own rare dis­ease as Sanofi, Boehringer com­mit $80M to launch new plat­form study

Over three decades of in­vest­ing, Luke Evnin has backed and ad­vised dozens of biotechs de­vel­op­ing med­i­cines. Now, the long­time VC is turn­ing his know-how and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.